2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid

A na-eji 2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid mee ihe dị ka etiti Eltrombopag.
Eltrombopag, nke GlaxoSmithKline (GSK) mepụtara na UK ma mechaa mebere ya na Novartis na Switzerland, bụ nke mbụ na naanị akwadoro obere molecule na-abụghị peptide TPO agonist n'ụwa.Ndị US FDA kwadoro Eltrombopag na 2008 maka ọgwụgwọ nke idiopathic thrombocytopenic purpura (ITP), na 2014 maka ọgwụgwọ nke anaemia siri ike (AA).Ọ bụkwa ọgwụ izizi nke US FDA kwadoro maka ọgwụgwọ AA n'ime afọ 30 na-adịbeghị anya.
Na december2012, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na-arịa ọrịa ịba ọcha n'anya C (CHC), nke mere na ndị ọrịa ịba ọcha n'anya C na-arịa ọrịa na-adịghị mma n'ihi ọnụ ọgụgụ platelet dị ala nwere ike ịmalite ma nọgide na-enwe usoro ọgwụgwọ interferon dabeere na ọgwụgwọ maka ọrịa imeju.Na Febụwarị 3,2014, GlaxoSmithKline kwupụtara na FDA nyere ntozu ọgwụgwọ ọgwụgwọ ọgwụgwọ Eltrombopag maka ọgwụgwọ hemopenia na ndị ọrịa nwere nnukwu akwụkwọ kemịkal aplastic anaemia (SAA) bụ ndị na-anabataghị nke ọma na immunotherapy.Na August 24, 2015, US FDA kwadoro Eltrombopag maka ọgwụgwọ thrombocytopenia na ndị okenye na ụmụaka dị afọ 1 na karịa na-adịghị ala ala thrombocytopenia (ITP) ndị na-enweghị nzaghachi zuru oke na corticosteroids, immunoglobulins ma ọ bụ splenectomy.Na Jenụwarị 4, 2018, a kwadoro Eltrombopag ka edepụta ya na China maka ọgwụgwọ nke thrombocytopenia nke mbụ na-alụso ọrịa ọgụ (ITP).